Varenicline: Quantifying the risk

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 12, 2011, Pages 1404-1405

  Squire, Edward N ^a  

^a Moore Free Care Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; META ANALYSIS (TOPIC); STATISTICAL ANALYSIS; UNITED STATES; CHEMICALLY INDUCED DISORDER; NOTE;

BENZAZEPINES; CARDIOVASCULAR DISEASES; HUMANS; NICOTINIC AGONISTS; QUINOXALINES;

EID: 80052531241     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.111-2070     Document Type: Letter

References (4)

1. Singh S., Loke Y.K., Spangler J.G., et al. Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. CMAJ 2011;183:1359-1366
2. Woods D.J., Caswell M.D. Varenicline: Quantifying the risk. CMAJ 2011;183:1404.
3. Hutton J.L. Misleading statistics: The problems surrounding number needed to treat and number needed to harm. Pharm Med 2010;24:145-149
4. Josefbert H. Approval package for: application number NDA 21-928 [clinical safety review: varenicline tartrate]. Rockville (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2006. p. 277, 402. Available: www .access-data .fda.gov/drugsatfda -docs/nda/2006 /021928 -s000 -Chantix-MedR.pdf.